Data Privacy Statement
This privacy statement of Boehringer Ingelheim International GmbH (hereafter "Boehringer Ingelheim") describes what personal data are collected by this website and how these data are processed.
Search
Application Platform Data privacy statement
(Application Platform) Data Privacy Statement | Boehringer Ingelheim Careers and Job Opportunities
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
J-Code Issued for SPEVIGO
Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults
Low-WAC interchangeable biosimilar is now available
Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.
From garage start-up to global pharma: combining strengths to advance regenerative medicine
Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.
Fighting COVID-19 | COVID-19 | Boehringer Ingelheim US
Read more on how Boehringer Ingelheim's work in developing vaccinations for animals has led us to support the pharma industry with the COVID-19 pandemic.
Our Work with the Gates Foundation | COVID-19 | Boehringer Ingelheim US
With global life science companies, we are joining the COVID-19 Therapeutics Accelerator of the Bill & Melinda Gates Foundation to fight the pandemic.
Meet the Animal Health Partnering Team
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
Nintedanib Study: Systemic Sclerosis & Lung Fibrosis | Boehringer Ingelheim US
Boehringer Ingelheim today announced that the first patient was enrolled in the SENSCIS™ (Safety and Efficacy of Nintedanib in SystemicSClerosIS) study.
Help in all situations in life
Boehringer Ingelheim focuses on the wellbeing of its employees – and is therefore also a "Global Top Employer 2023".
A Holistic Approach to Cardio-Renal-Metabolic Care | Boehringer Ingelheim US
Our Blueprint for Constructing a Holistic Approach to Cardio-renal-metabolic Care
Disability Inclusion at Work: Top Score | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim receiving a 100 score with Disability:IN’s “Best Place to Work for Disability Inclusion” for the 5th year!
Generalized pustular psoriasis: The importance of support and collaboration to promote advances in the GPP community
Dr Emmanuelle Clerisme-Beaty, Boehringer Ingelheim’s Therapeutic Area Inflammation Head of Medicine, in conversation with Dr Bruce Strober MD, PhD
Once-Daily Dosing for Most Diabetic Dogs | Boehringer Ingelheim US
Find out more on the BI PROZINC® (protamine zinc recombinant human insulin) for most canine diabetics, a breakthrough for pet owners with diabetic dogs.
OFEV® (nintedanib) Data in Patients with ILDs | Boehringer Ingelheim US
Studies from American Thoracic Society Congress show the proportion of patients with 10% or greater declines in lung function were lower in the OFEV group.
Positive results reported in HER2 mutated lung cancer
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
Grass Roots
Grass Roots
Global Careers Page | Boehringer Ingelheim
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
What we do
Boehringer Ingelheim is a multinational corporation with divisions dedicated to Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing.
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Transboundary and Emerging Diseases | Boehringer Ingelheim US
Click here to find out more on how Boehringer Ingelheim fights transboundary and emerging diseases through cutting-edge technologies.
Schizophrenia: Trial Results Show Advance in Cognition | BI US
Boehringer Ingelheim today announced the results from a 12-week, placebo-controlled Phase II trial, that demonstrate BI 425809 met its primary endpoint.
AI-Driven Model Validated to Predict Risk of CKD Progression
Boehringer Ingelheim and Carelon Research conducted the first large-scale U.S. validation of a new AI-driven tool to predict the risk of CKD progression.
Data Career
Data science at Boehringer Ingelheim is more than just solving fascinating problems. A chance to provide innovative solutions that bring value and hope to people.